Troglitazone (CS-045)

Catalog No.S8432 Synonyms: Rezulin, Romglizone, Prelay, Romozin

For research use only.

Troglitazone (Rezulin, Romglizone, Prelay, CS045, Romozin) is a potent agonist for the peroxisome proliferator-activated receptor-(PPAR) that is a ligand activated transcription factor regulating cell differentiation and growth. Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells. Troglitazone prevents RSL3-induced ferroptosis and lipid peroxidation in Pfa1 cells.

Troglitazone (CS-045) Chemical Structure

CAS No. 97322-87-7

Selleck's Troglitazone (CS-045) has been cited by 3 Publications

Purity & Quality Control

Choose Selective PPAR Inhibitors

Other PPAR Products

Biological Activity

Description Troglitazone (Rezulin, Romglizone, Prelay, CS045, Romozin) is a potent agonist for the peroxisome proliferator-activated receptor-(PPAR) that is a ligand activated transcription factor regulating cell differentiation and growth. Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells. Troglitazone prevents RSL3-induced ferroptosis and lipid peroxidation in Pfa1 cells.
Targets
Ferroptosis [6] PPAR [1]
In vitro

Troglitazone significantly inhibits cell growth by cell cycle arrest and apoptotic cell death. Troglitazone also downregulates surface expression of CD97, a novel dedifferentiation marker, in FTC-133 cells and upregulated sodium iodide symporter (NIS) mRNA in TPC-1 and FTC-133 cells. Troglitazone, a PPARγ agonist, induces antiproliferation and redifferentiation in thyroid cancer cell lines[1]. Troglitazone induces Erk phosphorylation in human prostate cancer cells via a PPARγ-independent signaling pathway[2]. TGZ(Troglitazone) up-regulates nitric oxide synthesis, induces the p53 pathway, inhibits cholesterol biosynthesis, induces p21 cyclin-dependent kinase inhibitor, has antioxidant function, and activates extracellular signal-regulated protein kinase (ERK) in a PPARγ-independent manner. TGZ induces Egr-1 expression by transcriptional and post-transcriptional regulation. Egr-1 induction by TGZ results in the increase of binding affinity and transactivation of the promoter containing Egr-1 consensus sequences, thereby possibly inducing other anti-tumorigenic proteins[3].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3-L1 cells MmfsSpVv[3Srb36gZZN{[Xl? MonvSYZn\WO2aY\lJINwdmOnboTyZZRqd25iZn;yJFUxLSCnbnjhcoNmdWWwdDDv[kBqdnO3bHnuMYlv\HWlZXSgeJJq\2y7Y3XybYRmKGGlY4XteYxifGmxbjDpckA{XDNvTEGgZ4VtdHNuIFXDOVA:OC5zMzFOwG0> MVm5OVk6OjRz
PC12 cells Mmi3VJJwdGmoZYLheIlwdiCjc4PhfS=> MXnDc45k\W62cnH0bY9vKHKncYXpdoVlKG[xcjC1NEUhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hWENzMjDj[YxteyC3c3nu[{B{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR|UxRTF3IN8ccS=> MnvQNVUyODl4NEi=
A549 M1nhe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnzqTY5pcWKrdHnvckBw\iCqdX3hckBtfW6pIHPhcoNmeiClZXzsJIxqdmViKFG1OFkqKGK7IEWwKUBqdiC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUG1JO69VQ>? NH7WelkyPTR3NEKzOC=>
3T3L1 cells M4GwS2Z2dmO2aX;uJIF{e2G7 NUTqb5BHUW6lcnXhd4UhcW5iMj3k[Y95gWeudXPvd4UhfXC2YXvlJIlvKG2xdYPlJFNVO0xzIHPlcIx{KGG2IEOgeW0h[nlibHnxeYllKHOlaX70bYxt[XSrb36gZ492dnSnch?= M2DtOVE5PDd5NUC3
ST-13 cells NHXic|lHfW6ldHnvckBie3OjeR?= MWW1JO69VQ>? MXSxNUBl[Xm| M3\hSWlv\HWldHnvckBw\iCycnXh[Ilxd2O7dHWg[Iln\mW{ZX70bYF1cW:wIHnuJI1wfXOnIGPUMVE{KGOnbHzzJIF{e2W|c3XkJIF{KGyrcHnkJIFk[3WvdXzheIlwdiCjdDC1JJVOKHerdHjpckAyOSCmYYnzJIJ6KG:rbDDy[YQue3SjaX7pcochemWuYYTpeoUhfG9iY3;ueJJwdA>? NF3xbpEyQTJ4OEW4Oy=>
HEK293 cells MVrGeY5kfGmxbjDhd5NigQ>? NHXUblFC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBz\WOncITvdkBqdnSncnHjeIlwdiC5aYToJJN1\XKxaXSgdoVk\XC2b4KgZ49i[3SrdnH0c5IuOSCkeTDFXWZRKGKjc3XkJJJmeG:{dHXyJIdmdmViYYPzZZk> NUW0SpJnOTZ4OECxOVk>
MA104 cells MmCwR5l1d3SxeHnjbZR6KGG|c3H5 MU[yOEBp NYS4cGpYS3m2b4TvfIlkcXS7IHHnZYlve3RibX;ub4V6KE2DMUC0JINmdGy|IHHmeIVzKDJ2IHjyd{whXER3ME2xPE42KM7:TR?= MYCyNlM3PTRzMR?=
MDA-MB-231 cells MoP1VJJwdGmoZYLheIlwdiCjc4PhfS=> NHLIO5MzPCCq MnjGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbI9zdW:wZT3pcoRmeGWwZHXueEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU44KM7:TR?= MkjWNlI1ODl7Nki=
MCF7 cells MlL0VJJwdGmoZYLheIlwdiCjc4PhfS=> NUO3SYNVOjRiaB?= M1nOd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIhwem2xbnWt[IVx\W6mZX70JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM2NjRizszN NHG5VVIzOjRyOUm2PC=>
HepG2 cells Mn7FSpVv[3Srb36gZZN{[Xl? M2TzTVIxKGh? MkLwWJJidnOjY4TpeoF1cW:wIH;mJGdCVDRvZoXz[YQhWFCDUnfhcY1iKEyERDDlfJBz\XO|ZXSgbY4hUGWyR{KgZ4VtdHNiYX\0[ZIhOjBiaILzJIJ6KGy3bXnu[ZNk\W6lZTDhd5NigSxiRVO1NF0xNjd|IN88US=> NVnhNpZjOjJ|OEGwOFc>
LNCAP cells NXOyT3BYS3m2b4TvfIlkcXS7IHHzd4F6 NFPRclYzPCCq M{\OXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPS0GSIHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NlIh|ryP M3nsclIzPTR4MkC4
PC3 cells MWDDfZRwfG:6aXPpeJkh[XO|YYm= M{fXWVI1KGh? NYLHXos4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9N|Ah|ryP NYC0TYVOOjJ3NE[yNFg>
HepG2 cells NHLKdllHfW6ldHnvckBie3OjeR?= NHrDcpI2OCEQvF2= MmP2NlQhcA>? M3n6dmlv\HWldHnvckBw\iCyNUOgdJJwfGWrbjDs[ZZmdCCrbjDoeY1idiCKZYDHNkBk\WyuczDheEA2OCC3TTD1dEB1dyB{NDDodpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?= NEex[HIzPTh3MUmzPS=>
CV-1 cells NFrWfnFHfW6ldHnvckBie3OjeR?= MlPQRYN1cX[jdHnvckBw\iCyZYLvfIl{d22nIIDyc4xq\mW{YYTvdkBi[3SrdnH0[YQhemWlZYD0c5Ih\2GvbXGgcYVie3W{ZXSgZpkhcW6mdXP0bY9vKG:oIEWwKUBw\iCvYYjpcZVuKGGua3HsbY5mKHCqb4PwbIF1[XOnIHHjeIl3cXS7LDD0doFve2[nY4Tpc44h[XO|YYmgbY4hS1ZvMTDj[YxteyxiRVO1NF0xNjV|N{CzJO69VQ>? NHHzcIg6QDN4NkKw
CHO cells M3fOXmZ2dmO2aX;uJIF{e2G7 M2ezNVI1KGh? M2qyZmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmejbX3hJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiY3:teJJidnOoZXP0[YQhf2m2aDDwS2w{NVCSUlWzMXRMNWy3YzDhd5Nme3OnZDDhd{B1emGwc3HjeIl3[XSrb36gZYZ1\XJiMkSgbJJ{KGK7IH\pdoVndHlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUCuOFQh|ryP NUjW[HB{OjJ|NEK2NlQ>
HepG2 cells NF;kPG9HfW6ldHnvckBie3OjeR?= M{SzTlAvPS1zMj61JO69VQ>? M3v5cmFod26rc4SgZYN1cX[rdImgZZQhWFCDUnfhcY1iKGmwIHj1cYFvKEincFeyJINmdGy|IHHzd4V{e2WmIHHzJIRwf25vcnXneYxifGmxbjDv[kBodHWlb4PlMVYueGixc4DoZZRie2ViYYSgNE42KHSxIEGyMlUhfU1iYomgdoVidC22aX3lJHBEWiCvZYToc4Q> M2LyR|IzOzR{NkK0
3T3L1 cells M3LufGZ2dmO2aX;uJIF{e2G7 NIPBS2RC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDtc5V{\SB|VEPMNUBk\WyuczygSWM2OD1zIN88US=> MkjyNlE1QTNyN{O=
HepG2 cells M2DrXGZ2dmO2aX;uJIF{e2G7 NWOwSYtvOC53LUGyMlUh|ryP Ml;vRYdwdmm|dDDhZ5Rqfmm2eTDheEBRWEGUZ3HtcYEhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94di2{ZXf1cIF1cW:wIH;mJJBpd3OyaH;lco9teHm{dY\heIUh[2G{Yn;4fYtqdmG|ZTDheEAxNjVidH:gNVIvPSC3TTDifUBz\WGuLYTpcYUhWEOUIH3leIhw\A>? MljONlI{PDJ4MkS=
HepG2 cells NHK3elRHfW6ldHnvckBie3OjeR?= NEXtO2tC\2:waYP0JIFkfGm4aYT5JIF1KFCSQWLnZY1u[SCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBxcG:|cHjv[Y5wdHC7coX2ZZRmKGOjcnLvfJlscW6jc3WgcXJPSSCkeTDSWE1RS1JiYX7hcJl{cXN? MYeyNlQzPDNyMB?=
HEK293T cells NGXrXXlHfW6ldHnvckBie3OjeR?= MUHJcohq[mm2aX;uJI9nKG2xdYPlJGlldzJidILhcpNn\WO2ZXSgbY4hUEWNMkmzWEBk\WyuczD1d4lv\yCOLYTyfZB1d3CqYX6gZZMhe3Wkc4TyZZRmKGG|c3Xzd4VlKGG|IHv5cpVz\W6rbnWg[o9zdWG2aX;uJIFnfGW{IES1JI1qdnNiYomgd5Bm[3S{b4Doc5RwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUSuOUDPpG1? MkXFNlMyOjJ6NkW=
HepG2 cells M2jnWmZ2dmO2aX;uJIF{e2G7 MV\B[49vcXO2IHHjeIl3cXS7IHH0JHBRSVKpYX3tZUBqdiCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDkc5dvemWpdXzheIlwdiCxZjDncJVkd3OnLU[tdIhwe3CqYYThd4UhdVKQQTDifUBTXC2SQ2KgZY5idHm|aYO= M2LWZVIzPDJ2M{Cw
HEK293 cells M{fBUmZ2dmO2aX;uJIF{e2G7 MYDBZ5RqfmG2aX;uJI9nKFCSQWLnZY1u[SC2cnHud4Zm[3SnZDDpckBJTUt{OUOgZ4VtdHNiYX\0[ZIhOThiaILzJIJ6KG[rcnXmcJkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lMYJie2WmIHz1cYlv\XOlZX7j[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;sMEBGSzVyPUCuOEDPxE1? MVmyNVgxODh3Nh?=
rat ventricular myocytes MWLGeY5kfGmxbjDhd5NigQ>? MXzJcohq[mm2aX;uJI9nKExvdInw[UBk[WylaYXtJINp[W6wZXygcYVie3W{ZXSgeZNqdmdid3jvcIUu[2WubDDwZZRkcCClbHHtdEBqdiC{YYSgeoVvfHKrY4XsZZIhdXmxY4n0[ZMtKEmFNUC9PU42KM7:TR?= MUeyNlc3OTByMB?=
HepG2 (DPX-2) cells MWHGeY5kfGmxbjDhd5NigQ>? NHjRbHMzPCCq MoXJRYN1cX[jdHnvckBw\iCqdX3hckBRYFJiZYjwdoV{e2WmIHnuJIh2dWGwIFjldGczKCiGUGitNkkh[2WubIOgZZN{\XO|ZXSgZZMhcW6mdXP0bY9vKG:oIFPZVFNCPCCjZoTldkAzPCCqcoOgZpkhdHWvaX7ld4NmdnRiYX7hcJl{cXNuIFXDOVA:Pi57IN88US=> MkfWNlA6PjZyNEO=
CV1 cells NXKxWoJYTnWwY4Tpc44h[XO|YYm= NXzhTFdHXHKjboPhZ5RqfmG2aX;uJI9nKGi3bXHuJHBRSVKpYX3tZUBmgHC{ZYPz[YQhcW5iYX\ybYNidiCpcnXlckBud26tZYmgR3YyKGOnbHzzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkSg{txO NEiwNG4zOjV5OUSyNC=>
CHO cells NYXvXpROTnWwY4Tpc44h[XO|YYm= Mm\kRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDy[YNwdWKrbnHueEBRWEGUZ3HtcYEh\XiycnXzd4VlKGmwIFPIU{Bk\WyuczDjc5Rz[W6|ZnXjeIVlKHerdHigdGdNOy2SUGLFN{1VUy2udXOgdoVxd3K2ZYKgZZN{\XO|ZXSgZZMh[mW2YT3nZYxi[3Sxc3nkZZNmKGGldHn2bZR6KGG2IHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIHLhd4VlKHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OD1yLkS0JO69VQ>? MYWyNlQzPDNyMB?=
HepG2 cells MYnGeY5kfGmxbjDhd5NigQ>? NXHHeXVyXHKjboPhZ5RqfmG2aX;uJI9nKEeDTESt[pV{\WRiUGDBVodidW2jIHzp[4Fv\CCkaX7kbY5oKGSxbXHpckB1emGwc3\lZ5Rm\CCrbjDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB{MDDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPUCuO|Ih|ryP M4D2SFI{ODNzNUm2
HEK293 cells MWrGeY5kfGmxbjDhd5NigQ>? Mn\0NVAh|ryP NGG1VIczPCCq MmXEWJJidnOjY4TpeoF1cW:wIH;mJHBRSVJvZ3HtcYEhfHKjboPm[YN1\WRiaX6gTGVMOjl|IHPlcIx{KGG2IEGwJJVOKGGodHXyJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl? NHf5UHAzOjV5OUS4OC=>
Assay
Methods Test Index PMID
Western blot ASCT2 / GLS1 ; c-Myc 25872876
Growth inhibition assay Cell viability 25872876
In vivo

Troglitazone is an effective antidiabetic drug with a fundamentally new mechanism of action. However, within a year after its widespread use, individual cases of liver injury and failure are reported[5]. TGZ significantly inhibits tumor growth of human colorectal cancer cells (HCT-116), human breast cancer cells (MCF-7), and human prostate cancer cells (PC-3) in immunodeficient mice[3]. Troglitazone attenuates pancreatic damage and inflammation in experimental chronic pancreatitis[4].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: Thyroid cancer cell lines TPC-1, FTC-133, FTC-236, FTC-238, XTC-1 and ARO82-1 cell lines
  • Concentrations: 5, 10, 20, 40 μM
  • Incubation Time: 0, 2, 4, and 6 days
  • Method:

    Growth experiments are done in a 96-well plate in hexaplicate. Cells at 85%-100% confluency are harvested with 1×Trypsin/EDTA solution and seeded into a 96-well plate at 3-5×103 cells per well depending upon growth rate and maintained in 200 μL H5 medium in a humidified incubator. After 24 hours, cells are incubated with different concentrations of troglitazone and the media was changed daily. Colorometric dimethyl-thiazol-diphenyltetrazolium bromide (MTT) proliferation assays are performed at 0, 2, 4, and 6 days after treatment. MTT (400 μg/mL) is added to each well and incubated for 3 hours. It is solubilized with 0.04 N HCl/iso-propanol/3% SDS and incubated for 1 hour. The optical densities in the 96-well plates are determined using an enzyme-linked immunosorbent assay (ELISA) microplate reader at 595 nm/620 nm.

Animal Research:

[4]

  • Animal Models: C57BL/6 mice
  • Dosages: 0.2% (with chow)
  • Administration: oral administration

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
1% CMC Na
For best results, use promptly after mixing.

30mg/mL

Chemical Information

Molecular Weight 441.54
Formula

C24H27NO5S

CAS No. 97322-87-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Troglitazone (CS-045) | Troglitazone (CS-045) ic50 | Troglitazone (CS-045) price | Troglitazone (CS-045) cost | Troglitazone (CS-045) solubility dmso | Troglitazone (CS-045) purchase | Troglitazone (CS-045) manufacturer | Troglitazone (CS-045) research buy | Troglitazone (CS-045) order | Troglitazone (CS-045) mouse | Troglitazone (CS-045) chemical structure | Troglitazone (CS-045) mw | Troglitazone (CS-045) molecular weight | Troglitazone (CS-045) datasheet | Troglitazone (CS-045) supplier | Troglitazone (CS-045) in vitro | Troglitazone (CS-045) cell line | Troglitazone (CS-045) concentration | Troglitazone (CS-045) nmr